A Study Comparing Iberdomide and Lenalidomide After Stem Cell Transplant for Multiple Myeloma
Phase 3
1,216
about 13 years
18+
44 sites in CO, FL, GA +15
What this study is about
Researchers are testing whether iberdomide or lenalidomide maintenance therapy, after autologous stem cell transplant (ASCT), is more effective in people with newly diagnosed multiple myeloma. The trial will last approximately 4 years and involve about 1200 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Iberdomide
- 2.Take Lenalidomide
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
lenalidomide (Immunomodulatory drug; affects immune system and cancer cells (exact mechanism unclear))
oral (Oral Capsule)
Primary: Progression-free survival (PFS)
Secondary: Achievement of CR or better and maintaining MRD-negative status in 2 bone marrow aspirate assessments that are a minimum of 1 year apart, without any examination showing MRD positive status in between assessments, Achieving MRD negativity in participants with CR or better at any time after the date of randomization, Achieving minimal residual disease (MRD) negativity in participants with complete response (CR) or better at 12 (± 3) months of maintenance treatment, Area under the iberdomide plasma concentration-time curve within a dosing interval AUC (TAU), Best response achieved prior to progressive disease (PD), Conversion from MRD positive to MRD negative in participants with CR or better, Maximum iberdomide concentration (Cmax), Number of participants with adverse events (AEs)
Oncology